Skip to main navigation
  • Investors & News
    • Investors Overview
    • Press Releases
    • Events
    • Governance
    • Financial Information
    • Stock Information
    • FAQs
    • Contact Us
  • Careers
  • Contact Us
  • Share
logo
  • About Omeros
    • About Omeros
    • Leadership
  • Science
    • Research Areas
    • Discovery Technologies
    • Scientific
      Publications
  • Pipeline
    • Pipeline Overview
    • OMIDRIA®
    • Narsoplimab
      (OMS721)
    • OMS824
    • OMS405
    • OMS527
    • OMS906
    • MASP-2, MASP-3,
      MASP-2/3
    • GPR174
    • GPR161
  • Product
    • OMIDRIA®
  • Patients
    • Commitment
      to Patients
  • Search
  • Investors & News
    • Investors Overview
    • Press Releases
    • Events
    • Governance
    • Financial Information
    • Stock Information
    • FAQs
    • Contact Us
  • Careers
  • Contact Us
  • Share

Investor Relations

  • Press Releases
  • Events
    • Upcoming Events
    • Archived Events
  • Governance
    • Highlights
    • Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Financial Information
    • Quarterly Results
    • Annual Reports
    • Proxy Statements
    • SEC Filings
    • Analyst Coverage
    • Presentations & Documents
  • Stock Information
    • Stock Quote
    • Stock Chart
    • Historical Prices
    • Investment Calculator
  • FAQs
  • Contact Us

Event Details

OMS302 Phase 3 Results Conference Call

Tuesday, March 13, 2012 09:00 AM EDT

Click here for webcast

Live Teleconference Information

Primary # -
866.788.0541
Secondary # -
857.350.1679
Passcode -
98382880

Replay Teleconference Information

Start Date -
Mar 13, 2012 at 9:30 AM EDT
Primary # -
888 286.8010
Secondary # -
617 801.6888
Passcode -
35583097

Omeros logo©2022 Omeros Corporation, All rights reserved.

  • Site Map
  • Contact Us
  • Privacy Policy
  • Legal

  • Investors & News
    • Investors Overview
    • Press Releases
    • Events
    • Governance
    • Financial Information
    • Stock Information
    • FAQs
    • Contact Us
  • Careers
  • Contact Us
  • Share
  • About Omeros
    • About Omeros
    • Leadership
  • Science
    • Research Areas
    • Discovery Technologies
    • Scientific
      Publications
  • Pipeline
    • Pipeline Overview
    • OMIDRIA®
    • Narsoplimab
      (OMS721)
    • OMS824
    • OMS405
    • OMS527
    • OMS906
    • MASP-2, MASP-3,
      MASP-2/3
    • GPR174
    • GPR161
  • Product
    • OMIDRIA®
  • Patients
    • Commitment
      to Patients

We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. If you continue to browse this site, you will accept our use of cookies. For more information, please read our Privacy Policy.
Agree

You are now leaving Omeros.com

Omeros makes no representation as to the accuracy of the information on sites we do not own or control and does not recommend or endorse content on any third-party websites. Your use of a third-party website is at your own risk and subject to the terms and conditions of that site.

Continue

© 2022 Omeros All rights reserved